SNORD116 and SNORD115 change expression of multiple genes and modify each other's activity

Marina Falaleeva, Justin Surface, Manli Shen, Pierre de la Grange, Stefan Stamm

Abstract

The loss of two gene clusters encoding small nucleolar RNAs, SNORD115 and SNORD116 contribute to Prader–Willi syndrome (PWS). The most common syndromic form of obesity in humans, SNORD115 and SNORD116 are considered to be orphan C/D box snoRNAs (SNORDs) as they do not target rRNAs or snRNAs. SNORD115 exhibits sequence complementarity towards the serotonin receptor 2C, but SNORD116 shows no extended complementarities to known RNAs. To identify molecular targets, we performed genome-wide array analysis after overexpressing SNORD115 and SNORD116 in HEK 293T cells, either alone or together. We found that SNORD116 changes the expression of over 200 genes. SNORD116 mainly changed mRNA expression levels. Surprisingly, we found that SNORD115 changes SNORD116's influence on gene expression. In similar experiments, we compared gene expression in post-mortem hypothalamus between individuals with PWS and aged-matched controls. The synopsis of these experiments resulted in 23 genes whose expression levels were influenced by SNORD116. Together our results indicate that SNORD115 and SNORD116 influence expression levels of multiple genes and modify each other's activity.

1. Introduction

Prader–Willi syndrome (PWS) is a frequent genetic form of obesity in humans, characterized by hyperphagia, short stature, hypogonadism, thick saliva, obsessive–compulsive behavior, and hormonal imbalances (Butler et al., 2006; Cassidy et al., 2012). PWS patients typically undergo several stages of disease: severe infantile hypotonia with poor suck and failure to thrive after birth, followed by early-childhood onset obesity and hyperphagia. In addition, there are developmental delays and/or mild intellectual disability (Butler, 2011; Cassidy et al., 2012).

PWS is caused by the loss of gene expression from a maternally imprinted region on chromosome 15 (15q11.2–q13) that contains several protein coding genes, as well as clusters of C/D box snoRNAs (SNORDs). The two SNORD clusters encode SNORD115 and SNORD116. Each cluster contains 47 and 28 similar copies, respectively. Recently, several patients with Prader–Willi like phenotype were described to have microdeletions affecting the SNORD115 and SNORD116 clusters (Fig. 1A). All microdeletions encompass the SNORD116 cluster, suggesting a central role of these SNORDs. Although these patients share nutritional features, hypogonadism, behavioral problems and intellectual disability with PWS patients, the patients with microdeletions have a tall stature as children, a large head circumference and hand features atypical for PWS, suggesting that genes other than SNORD116 contribute to PWS (Sahoo et al., 2008; de Smith et al., 2009; Duker et al., 2010; Bieth et al., 2015). Small nucleolar RNAs (snoRNAs) are 60–300 nt long non-coding RNAs that accumulate in the nucleolus. Based on characteristic sequence elements, snoRNAs are classified as C/D box and H/ACA box snoRNAs. In humans, C/D box snoRNAs (SNORDs) are mostly derived from intronic regions, located 70–90 nt upstream of the 3′ splice site of an exon in a hosting gene (Fig. 1B). After the splicing reaction, introns are excised as lariats that are opened and subsequently degraded. snoRNAs escape this degradation by forming a protein complex (Hirose and Steitz, 2001).

 Canonical C/D box snoRNAs (SNORDs) form a protein complex that includes NOP56, NOP58 and NHP2L1, as well as fibrillarin acting as the RNA methyltransferase. RNA secondary structures formed by C (RUGAUGA, R = purine) and D (CUGA) boxes help the assembly of proteins to form a snoRNA–protein complex (snoRNP). This snoRNP exposes an RNA element, the antisense box that hybridizes to the target RNA. In the target RNA, a distinct ribose residue is 2′-O-methylated by the RNA methyltransferase fibrillarin (reviewed in (Smith and Steitz, 1997; Kiss, 2002; Matera et al., 2007; Reichow et al., 2007; Brown et al., 2008) and available in the LBME snoRNA database (Lestrade and Weber, 2006)).
However, about half of the 267 human C/D box snoRNAs including SNORD115 and SNORD116 clusters show no sequence complementarity towards other ncRNAs and are thus orphan, suggesting additional functions. SNORD115 shows an 18 nt sequence complementarity towards the serotonin receptor 2C and more limited complementarities to several other pre-mRNAs and changes alternative splicing in these genes (Kishore and Stamm, 2006; Kishore et al., 2010). In addition, RNase protection experiments show that both SNORD115 and SNORD116 form shorter RNA fragments and bind non-canonical proteins involved in RNA metabolism, such as hnRNP (Kishore et al., 2010; Soeno et al., 2010). However, immunoprecipitates of fibrillarin contain SNORD116 and SNORD115, suggesting that a fraction of SNORDs forms canonical snoRNA complexes (Soeno et al., 2010; Bortolin-Cavaille and Cavaille, 2012). SNORD115 and SNORD116 are highly conserved in vertebrate species, whereas their flanking introns and hosting exons are poorly conserved (Kishore and Stamm, 2006). This indicates that they exhibit sequence-specific functions, but until now no target genes were discovered for SNORD116. Recently, deep-sequencing experiments showed that other SNORDs give rise to shorter fragments (Deschamps-Francoeur et al., 2014; Dupuis-Sandoval et al., 2015). Functionally, these orphan snoRNAs have been implicated in formation of miRNAs, regulation of
chromatin structure, alternative splicing and modulation of cell survival under oxidative stress (reviewed in Falaleeva and Stamm, 2013; Dupuis-Sandoval et al., 2015), which increases the variety of the biological functions of SNORDs.

Here we perform genome-wide array analysis to identify genes regulated by SNORD115/116. The analysis indicated that SNORD116 changes expression levels of over 200 genes. Unexpectedly, we found that SNORD115 influences the ability of SNORD116 to change target gene expression.

2. Material and methods

2.1. Construction of SNORD116 expression clones

For SNORD116 overexpression, we used the mouse copy orthologous to human SNORD116-1. We previously used mouse orthologs (MBII-52 and MBII-85) of SNORD115 and SNORD116, respectively as they are highly similar to the human SNORDs. Furthermore, SNORD115 was shown to regulate human genes (Kishore and Stamm, 2006; Kishore et al., 2010). MBII-85 is >98% identical to its human counterparts. Considering G:U base-pairs forming in RNA, MBII-85 has 94% identical binding capacity compared with human. The MBII-52 sequence is >93% identical to it’s human counterpart and has >96% identical binding properties. The mouse RNA is more similar to the particular human copy than some of the related human copies to each other.

The initial SNORD116 expression cassette that represents two exons with snoRNA embedded within the intron was synthesized by Biomatik, Wilmington, USA. The constructs contain the 380 nt or 2536 nt long natural intron for SNORD115 or SNORD116, respectively. To improve SNORD116 expression efficiency site-directed mutagenesis was performed using PCR primers (R-MBII-85 5′-SS: TGGACAGAATCCCTCATATA ACCTAATTTATCTACGAGTGC, F-MBII-85 5′-SS: TCAACTGCTTGAATGAT) to mutate 5′ splice site and PCR primers (R-MBII-85 3′-SS: GCAACCGCTAAGGAAAAAGAGAGACA TGGCCCT, F-MBII-85 3′-SS: GGGGCATGTTCTCTTTTCTCTTCACAGGG TTGCA) to mutate 3′ splice site. All constructs are available through Addgene (ID numbers 67631, 67643–67647).

2.2. Array analysis

The transfection of cells was performed for 40 h using 2 μg of plasmid DNA for about 2 × 10^5 cells in six-well plate using calcium phosphate transfection method (Stoss et al., 1999). RNA was isolated from HEK 293T cells using Total RNA RNeasy kit (Qiagen) and from brain section using RNeasy Lipid Tissue kit (Qiagen). For reverse transcription, the RNA was incubated at 50 °C for 5 min. A tenth part of the RT reaction was used for CDNA amplification. The reaction was performed in 20 μl and contained 10 pmol of specific forward and reverse primers, 200 μM dNTPs, 1x Taq polymerase buffer and 1 U of Platinum Taq DNA polymerase (Life Technology). The amplification was carried out in an Eppendorf PCR System Thermocycler under the following conditions: initial denaturation for 30 s at 94 °C, 30 cycles of touchdown PCR with 30 s at 94 °C, 30 s at (65 °C–55 °C for first 20 cycles and 55 °C last 10 cycles) and an extension of 60 s at 72 °C. After the last cycle, the reaction was held for 5 min at the extension temperature to complete the amplification of all products. Primers used were: ACOXL-S2:GGCTCCAGATGGACAGTACC; ACOXL-A2:AGG GTCGCTGTTGTGTCGGCT; CGD91-F1: GCTTGGTTGGTGGCT; CGD91-R1: GC ATTTGTCCTTTTGCTGAT; FIT2: GAGAGCTACTGCTACACACA AGC; R-FIT2: GAGAAGCTAAGCCGAGCCA; MAP2-F:CGTCACACTACA TTCACCT; MAP2-R: GTGTCACCTCCAGCCTG; NR1H2-R: GGC TCCAC TACAACCCTG; NR1H2-R2: TGGACTGTGCATTCTGCTGCT; F-PEX11A :CG ACTTCTGAAGGCACTCA; R-PEX11A:GGCTCAGCTGACACATTGACG; PRKCE-F: AGCTGGCTGTCTTTCACGAT; PRKCE-R: CTGCAATTGAGGAGAG; ST3GAL2-F1: AACCACCCACATTCTATG; ST3GAL2-R1: TC CAGATGTTGTCACCTG; ST3GAL2-R: AGTCATGGGCATCGATGTTG; TUBB4-R:TCCTCGCGGATCTTACTGAT; CYPIIE1-F2 :CTGGTACCTCCTTCTTCCCTCAGAGG TTGC

2.3. RNase protection analysis (RPA)

HEK 293T cells were transiently transfected with plasmids coding for MBII-52 and MBII-85 snoRNA (mouse orthologs of SNORD115-15 and SNORD116-1 respectively). Total RNA was isolated from cells using TRIzol LS reagent according to manufacturer’s protocol. As a probe, we used a uniformly labeled RNA against mouse chr7:59,520,283–59,520,365 for MBII-52 and chr7:59,861,729–59,861,827 for MBII-85, as previously described (Shen et al., 2011).

2.4. RT-PCR

1 μg of total RNA, 5 pmol of reverse primer and 20 μl of SuperScript III reverse transcriptase (Life Technology) were mixed in 20 μl of RT buffer. To reverse transcribe the RNA, the reaction was incubated at 50 °C for 50 min. A tenth part of the RT reaction was used for CDNA amplification. The reaction was performed in 20 μl and contained 10 pmol of specific forward and reverse primers, 200 μM dNTPs, 1x Taq polymerase buffer and 1 U of Platinum Taq DNA polymerase (Life Technology). The amplification was carried out in an Eppendorf PCR System Thermocycler under the following conditions: initial denaturation for 30 s at 94 °C, 30 cycles of touchdown PCR with 30 s at 94 °C, 30 s at (65 °C–55 °C for first 20 cycles and 55 °C last 10 cycles) and an extension of 60 s at 72 °C. After the last cycle, the reaction was held for 5 min at the extension temperature to complete the amplification of all products. Primers used were: ACOXL-S2:GGCTCCAGATGGACAGTACC; ACOXL-A2:AGG GTCGCTGTTGTGTCGGCT; CGD91-F1: GCTTGGTTGGTGGCT; CGD91-R1: GC ATTTGTCCTTTTGCTGAT; FIT2: GAGAGCTACTGCTACACACA AGC; R-FIT2: GAGAAGCTAAGCCGAGCCA; MAP2-F:CGTCACACTACA TTCACCT; MAP2-R: GTGTCACCTCCAGCCTG; NR1H2-R: GGC TCCAC TACAACCCTG; NR1H2-R2: TGGACTGTGCATTCTGCTGCT; F-PEX11A :CG ACTTCTGAAGGCACTCA; R-PEX11A:GGCTCAGCTGACACATTGACG; PRKCE-F: AGCTGGCTGTCTTTCACGAT; PRKCE-R: CTGCAATTGAGGAGAG; ST3GAL2-F1: AACCACCCACATTCTATG; ST3GAL2-R1: TC CAGATGTTGTCACCTG; ST3GAL2-R: AGTCATGGGCATCGATGTTG; TUBB4-R:TCCTCGCGGATCTTACTGAT; CYPIIE1-F2 :CTGGTACCTCCTTCTTCCCTCAGAGG TTGC

2.5. Patient tissue

Tissue was received from the NICHD Brain and Tissue Bank that has received consent for the donation of tissue for research from the legal next of kin of all donors described. The Brain and Tissue Bank adheres to the standard of the Institutional Review Board of the University of Maryland School of Medicine in Baltimore, Maryland. Consents are on file in the office of the NICHD Brain and Tissue Bank.

2.6. Statistical analysis

For RT-PCR validation, changes in the gene expression were analyzed using unpaired t-tests (Graph Pad Prism 6 Software).
3. Results

3.1. Construction of SNORD116 and SNORD115 expression clones

To analyze the influence of SNORD115 and SNORD116 on gene expression, we generated a series of cDNA constructs. The SNORD expression cassette consists of two non-coding exons flanking an intron that hosts the snoRNA under the control of a CMV promoter (Fig. 1A, B).

We transfected HEK 293T cells with the SNORD116 constructs and analyzed total RNA after 40 h of the transfection using RNase protection assay (RPA) (Fig. 1C). Endogenous SNORD116 is not detectable using RPA in HEK 293T cells. Transfecting a cDNA expressing wild-type SNORD116 results in detectable snoRNA expression that is however weaker than the expression observed in brain (Fig. 1D, E). We also overexpressed SNORD115 using this approach, as previously described (Kishore and Stamm, 2006; Kishore et al., 2010) and found that HEK 293T cells do not express SNORD115 endogenously (Fig. 1F, G).

To improve SNORD116 expression, we thus mutated splice sites into the mammalian consensus. The 5′ splice site was mutated from TGaaggcac to ACCaaagtat and the 3′ splice site form gttgggttcacag to ctttttcacag. Improvement of the 5′ splice site strongly increased SNORD116 expression, whereas changing the 3′ splice site had only a minor effect. Combining both splice site mutations showed no additional increase (Fig. 1D, E). Similar to previous reports (Shen et al., 2011), we observed shorter SNORD116 fragments using these constructs that reflect the situation in brain. We thus used the SNORD116 construct with the optimized 5′ splice site for further studies. The data show that SNORD116 expression levels can be controlled at the level of splice site quality.

3.2. Array analysis of SNORD overexpression in HEK 293T cells

To determine the effect of SNORDs missing in PWS on gene expression, we performed four different array experiments using SpliceArrays (Affymetrix). Splicearrays are genomewide oligonucleotide-based arrays that are built on exon-specific probes (Johnson et al., 2003). Importantly, these arrays contain exon junction probes. Thus, in addition to a deregulation in overall gene expression, they detect changes in alternative splicing.

In the first three experiments, we transfected HEK 293T cell with constructs coding for (i) SNORD115, (ii) SNORD116 and (iii) SNORD115 and SNORD116 together and compared them with overexpression of green fluorescent protein. The same amount of plasmid DNA was used in each experiment. The transfection of green fluorescent proteins controlled for equal amounts of promoter-containing plasmids transfected (Stoss et al., 1999). HEK 293T cells were used as they give high transfection efficiencies and express some neuronal markers (Lin et al., 2014). For each cell-based experiment three biological replicas were used. In the fourth experiment, we compared (iv) RNAs extracted from post-mortem posterior hypothalamus of PWS patients (two patients) and aged matched controls (three patients).

The overexpression of SNORD115 and SNORD116 was confirmed by RNase protection assay (Fig. 1D, F).

Overexpression of SNORD115 resulted in 10 changes in gene expression (Supplemental Data 1, note that all supplemental data are hyperlinked to the UCSD genome browser). In addition, we observed nine changes in alternative splicing that however could not be validated by RT-PCR. Overexpression of SNORD116 resulted in 274 changes in gene expression (Supplemental Data 2). For SNORD116, there were 47 changes in alternative cassette exon usage with low confidence that could not be validated by RT-PCR (data not shown). This suggests that the main effect of SNORD116 is on expression levels of mRNAs, not their splicing patterns.

We next overexpressed SNORD115 and SNORD116 together to determine the simultaneous effect of the SNORDs as in most PWS patients both SNORDs are missing. In this experiment, we observed a total of 415 changes in gene expression (Supplemental Data 3). Changes in alternative splicing were minor, with only one change predicted with high confidence, which could not be validated by RT-PCR. Unexpectedly, changes in gene expression caused by simultaneous overexpression of SNORD115 and SNORD116 did only partially (23 genes) overlap with the changes in gene expression caused by SNORD116 alone (Fig. 2). This suggests that SNORD115 can modify the action of SNORD116 on gene expression, suggesting that the major role for both snoRNAs is to work together to increase selected gene expression.

3.3. Array analysis of RNA isolated from PWS samples

We next compared the overall gene expression between PWS patients and aged matched controls in human posterior hypothalamus, the only currently available hypothalamic tissue. We choose hypothalamus, as dysfunctions in this brain region are the likely cause for most of the symptoms in PWS (Swaab, 1997). First, we confirmed the clinical diagnosis of PWS using RPA that confirmed the absence of SNORD115 and SNORD116 (Falaleeva et al., 2013). The comparison of PWS patient brains with aged matched genetically normal controls showed 5113 changes in gene expression (Supplemental Data 4). The high number of differences in hypothalamic tissue likely reflects differences between individuals. However, we saw an overlap of 23 genes with the overexpression of SNORD115/116 in HEK 293T cells (Fig. 2). A chi-squared test shows this overlap to be significant with a p-value of $7.35 \times 10^{-3}$. The direction of SNORD115/116 induced changes was mostly similar, i.e. they were either downregulated in PWS and up-regulated through SNORD115/116 overexpression, or up-regulated in PWS and downregulated in SNORD115/116.
expression (Fig. 2A, B; Supplemental Data 5). In addition we detected several changes that showed different directions (Supplemental Data 5).

This suggested that some of these expression changes were directly caused by the loss of SNORD115 and SNORD116. In summary, the loss of SNORD116 and SNORD115 expression in PWS caused mainly a deregulation in gene expression, not in alternative splicing.

3.4. Analysis of observed changes by RT-PCR

We next selected several regulated genes and validated observed changes by RT-PCR. To insure equal RNA loading, we measured TRAK2 gene expression since TRAK2 did not change in all array data sets (Supplemental Data 6). We found that changes in gene expression detected by the array resulted in changes determined by RT-PCR. However, for NR1H2, ACOXL, PEX11A, ST3GAL2 genes there was a discrepancy in the direction of the change. It is possible that the probesets of the array do not fully reflect the complexity of the transcripts. Similar to the array experiments, the RT-PCR analysis revealed a synergistic action between the SNORDs, as SNORD115 influenced the effect of SNORD116 on gene expression (Table 1). A t-test analysis using three biological replicates showed that the effect of SNORD115 on SNORD116 action was statistically significant for ST6GALNAC2, TUBB4, ACOXL and NR1H2 genes (Table 1). In all cases tested, the simultaneous expression of SNORD115 and SNORD116 increased expression of the target genes (Fig. 3). The genes up-regulated by SNORD115/116 are always higher expressed in normal patients compared with PWS subjects, where the SNORDs are missing. Thus, SNORD115/116 overexpression in cells reflects the situation in Prader–Willi patient samples.

In summary, the data indicate that SNORD116 and SNORD115 act synergistically to regulate the expression of several genes.

4. Discussion

4.1. SNORD115 and SNORD116 regulate gene expression levels

The Prader–Willi critical region contains two clusters of C/D box snoRNAs (SNORDs), SNORD116 and SNORD115. The best understood function of C/D box snoRNAs is the guidance of RNA methylation activity to RNA, using a defined part of this sequence, the antisense box. However, 137/267 human SNORDs have no sequence complementarity to known RNAs and are thus orphan (Dupuis-Sandoval et al., 2015).

SNORD115 shows an 18 nt sequence complementarity between its antisense box and the serotonin receptor 2C pre-mRNA. It was shown that SNORD115 regulates alternative splicing of this receptor, which likely contributes to the hyperphagia in PWS (Kishore and Stamm, 2006). Subsequent analysis based on bioinformatic prediction showed that SNORD115 regulates several other splicing events and importantly forms RNA–protein complexes that are different from the canonical snoRNPs. SNORD115 forms shorter RNAs and associates with hnRNPs (Kishore et al., 2010; Soeno et al., 2010), suggesting the formation of a non-canonical complex. The serotonin receptor 2C is not expressed in HEK 293T cells and shows a very weak expression in posterior hypothalamus. We thus could not detect changes in serotonin receptor 2C expression. Similarly, the changes in alternative splicing previously detected by RT–PCR were too small to reach statistical significance in the array analysis.

SNORD116 has been considered to be of particular importance for PWS, as patients with microdeletions in SNORD116 cluster show a phenotype related to PWS. The microdeletions have less severe phenotype than the full deletion of the PWS region (Cassidy et al., 2012). The molecular role of SNORD116 is not clear, as bioinformatic analysis does not indicate strong sequence complementarity to any known RNA. However, SNORD116 targets are predicted to be non-randomly associated with genes producing alternatively spliced mRNA isoforms (Bazeley et al., 2008).

To identify the effect of SNORD116 on gene expression, we therefore overexpressed SNORD116 in cells lacking endogenous SNORD116 expression. We found changes in gene expression in 274 genes. It is possible that some of these changes are not direct. Unexpectedly, we could not find any changes in alternative splicing that could be validated by RT-PCR. Measured by both RT-PCR and array intensity, the changes caused by SNORD116 are modest, less than twofold, similar to changes that were reported in a previous array experiment using lymphocytes from PWS subjects (Bittel et al., 2007).

Bioinformatic analysis did not reveal strong sequence complementarities between SNORD116 sequences and their target genes. Recently, it was found that SNORDs can activate protein kinase R, a kinase that is activated by double-stranded RNAs, including those formed by SNORDs (Yousef et al., 2015). It remains to be determined whether SNORD116 acts through such a mechanism, which will likely rely on limited sequence complementarity.

Almost all genes that we validated were up-regulated by SNORD116/115, suggesting that SNORD115/116 in general promotes either stability or production of target mRNAs. We were not able to find long stretches of sequence complementarity in these regulated genes and thus the mechanism of action remains elusive.

It has been suggested that SNORD115/SNORD116 containing regions form long ncRNA with snoRNA ends (Yin et al., 2012). Since we express only one copy of each SNORD, these long RNAs will not form and the effects we see were due to SNORD116/SNORD115 acting on the level of

Table 1

<table>
<thead>
<tr>
<th>Gene name</th>
<th>SNORD115 vs GFP</th>
<th>SNORD116 vs GFP</th>
<th>SNORD115 + 116 vs GFP</th>
<th>PWS vs control, brain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%change</td>
<td>p</td>
<td>%change</td>
<td>p</td>
</tr>
<tr>
<td>ST6GALNAC2</td>
<td>62.05</td>
<td>0.0002</td>
<td>184.4</td>
<td>0.0015</td>
</tr>
<tr>
<td>NR1H2</td>
<td>55.7</td>
<td>0.0736</td>
<td>80.0</td>
<td>0.0487</td>
</tr>
<tr>
<td>ACOXL</td>
<td>89.0</td>
<td>0.2860</td>
<td>98.99</td>
<td>0.7939</td>
</tr>
<tr>
<td>TUBB4</td>
<td>219.0</td>
<td>0.0350</td>
<td>121.5</td>
<td>0.0001</td>
</tr>
<tr>
<td>FIT2</td>
<td>99.06</td>
<td>0.9437</td>
<td>159.7</td>
<td>0.0003</td>
</tr>
<tr>
<td>PEX11A</td>
<td>165.0</td>
<td>0.0525</td>
<td>162.0</td>
<td>0.0010</td>
</tr>
<tr>
<td>MAP-2</td>
<td>133</td>
<td>0.0003</td>
<td>183.0</td>
<td>0.0039</td>
</tr>
<tr>
<td>PRKCE</td>
<td>103.4</td>
<td>0.0760</td>
<td>125.8</td>
<td>0.0056</td>
</tr>
<tr>
<td>ST3GAL2</td>
<td>103.8</td>
<td>0.0251</td>
<td>109.13</td>
<td>0.2266</td>
</tr>
<tr>
<td>CDG51</td>
<td>90.7</td>
<td>0.0048</td>
<td>118.2</td>
<td>0.5300</td>
</tr>
<tr>
<td>CVPR1</td>
<td>125.9</td>
<td>0.2168</td>
<td>107.25</td>
<td>0.7820</td>
</tr>
<tr>
<td>TRAK2</td>
<td>98.13</td>
<td>0.4067</td>
<td>102.8</td>
<td>0.9110</td>
</tr>
</tbody>
</table>

Target gene validation. The percent change compared with GFP control is tabulated for each gene, i.e. the expression level after GFP transfection is set to 100% and the changes in gene expression after SNORD transfection expressed as a ratio (% change). The p-values were calculated using an unpaired two-tailed t-test from at least three different experiments. The TRAK2 gene was used as a control, as its expression did not change in multiple array experiments (this work and Zhang et al., 2013; Shen et al., 2013; Convertini et al., 2014).
a short snoRNA. Similarly, our system will not detect changes caused by RNAs formed by the non-coding exons flanking the snoRNAs (Powell et al., 2013).

Some of the detected gene changes could be relevant for the observed phenotype. For example ST6GALNAC2 is a sialyltransferases adding sialic acid to glycoproteins. One of its known interactors is

Fig. 3. Validation of array data. Selected changes in gene expression were validated using RT-PCR. The statistical analysis of at least three biological replicas for cells and two biological samples for PWS is shown underneath the gels. Error bars indicate the standard deviations. We used TRAK2 expression as a loading control since it shows no changes in all array experiments. The y-axis is the % change relative to the transfection of a GFP-expressing construct.
Mucin 1 (Marcos et al., 2011), a component of saliva. Thus a defect in mucin glycosylation could contribute to changes in saliva seen in patients. Several genes identified (ACOX1, CYP1E1, FITZ, PEX11A) are involved in lipid degradation/metabolism and their deregulation could contribute to changes in metabolism.

4.2. SNORD115 and SNORD116 modify each other’s action on gene expression

To recapitulate the situation in PWS, overexpressed SNORD115 and SNORD116 simultaneously and surprisingly found that SNORD115 decreases the number and intensity of genes regulated by SNORD116. This finding was confirmed by RT-PCR using ten selected genes. In most cases SNORD115 enhances the increase of gene expression caused by SNORD116 (Table 1, Fig. 3). Using t-test analysis we found that the influence of SNORD115 on SNORD116-dependent genes is statistically significant for ST6GALNA2, TUBB4, ACOX1 and SNR112. However, the molecular mechanism for the modulation of both SNORDs is unclear, because no extensive sequence complementarities can be detected between SNORD115, SNORD116 and the four target genes. It is possible that SNORD115 and SNORD116 form heterodimers, which could be aided by binding proteins, as it is known that canonical C/D snoRNAs form dimers (Bleichert et al., 2009). The formation of heterodimers between SNORD115 and SNORD116, possibly aided by proteins could explain why SNORD115 modulates SNORD116's effects on gene expression.

The data could explain why a loss of SNORD116 through micro-deletions has a much milder phenotype than loss of both SNORD115 and SNORD116. There are only two PWS-patients published that due to micro-deletions do express SNORD115 but not SNORD116 (Fig. 1A). These patients are atypical, having a tall stature as a child, large head circumference, and lack of PWS facial gestalt and hand features atypical for PWS (Cassidy et al., 2012). Thus, both SNORD115 and SNORD116 contribute to the PWS disease etiology and should be considered for therapeutic development.

5. Conclusion

The two snoRNAs not expressed in Prader–Willi syndrome act together to regulate gene expression. SNORD116 has the largest effect on the abundance of mRNAs. Therapies aimed for PWS should preferentially target both SNORD115 and SNORD116 clusters.

Supplemental data to this article can be found online at http://dx.doi.org/10.1016/j.gene.2015.07.023. All gene coordinates in excel files are hyperlinked to the UCSC genome browser, allowing users to look up the respective genes. Of the 33,955 genes on the Affymetrix array, only 17,465 (52%) are annotated with a gene symbol to avoid ambiguities. Therefore some genes show no names but can be accessed through the hyperlink.

Acknowledgment

This work was supported by NIH01GM083187 (SS), R21ZH080035 (SS); NIGMS30GM110787, a grant from the Foundation for Prader-Willi Research, and a postdoctoral Fellowship 13POST16820024 from the American Heart Association (M.J.F.). This work utilized tissue from the NICHD Brain and Tissue Bank for Developmental Disorders (NICHD contract # HHSN275200900011C).

References


